Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS

J Chromatogr Sci. 2014 Jan;52(1):52-8. doi: 10.1093/chromsci/bms204. Epub 2013 Jan 4.

Abstract

A high-performance liquid chromatography-tandem mass spectrometry method was developed for the simultaneous determination of metformin (MET) and pioglitazone (PIO) in dogs. To increase the reliability of the method, moroxydine (IS-1) and rosiglitazone (IS-2) were used as internal standards for MET and PIO, respectively. The analytes were extracted from beagle dog plasma by a one-step protein precipitation. Chromatographic separation was performed on a Phenomenex Synergi POLAR-RP 80A column (250 × 4.6 mm, 4 µm). The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2. The lower limit of quantitation values were 2 and 1 ng/mL for MET and PIO, respectively. The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromatography, Liquid / methods*
  • Dogs
  • Drug Stability
  • Female
  • Limit of Detection
  • Linear Models
  • Male
  • Metformin / blood*
  • Metformin / chemistry
  • Metformin / pharmacokinetics
  • Pioglitazone
  • Reproducibility of Results
  • Tandem Mass Spectrometry / methods*
  • Thiazolidinediones / blood*
  • Thiazolidinediones / chemistry
  • Thiazolidinediones / pharmacokinetics

Substances

  • Thiazolidinediones
  • Metformin
  • Pioglitazone